High serum cholesterol (Cho) and triglyceride (TG) concentrations in dogs are caused by various factors such as lack of exercise, high fat diets, obesity, neutralization, age, diseases and breed \[[@r6], [@r21], [@r24]\]. Miniature Schnauzer and Shetland Sheepdog are breeds that are well known to have a high risk of contracting hypertriglyceridemia and hypercholesterolemia \[[@r13], [@r25]\]. These days, total Cho and TG concentrations are measured in animal clinics as part of health management for dogs, because they are correlated with some diseases such as diabetes mellitus, hypothyroidism, protein-losing nephropathy and liver disease \[[@r1], [@r7]\].

Canine serum lipid is transported in four groups of lipoproteins: chylomicrons (CM), very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) \[[@r7], [@r24]\]. In Japan, a lipoprotein analysis service is used for the measurement of canine lipid levels. When dogs require treatment, they are prescribed some lipid metabolism medicines that were developed for humans, such as Clinofibrate (CF) which is well known for treatment of high VLDL-TG concentration.

Fibrates are very effective for treating high VLDL-TG concentration. Their TG-lowering effect is caused by activation of the peroxisome proliferator activated receptor α (PPARα), the nuclear hormone receptor superfamily that regulates lipid and lipoprotein metabolism \[[@r16]\]. There have been various studies about the effects on dogs of fibrates such as Fenofibrate and Bezafibrate \[[@r3], [@r17]\], but there have been few epidemiological studies with CF.

In this study we have two objectives: (1) to assess how CF treatment improves lipid metabolism in dogs, and (2) to clarify whether the CF response is influenced by canine characteristics such as breed, age, sex, neuter status, or by the Body Condition Score (BCS) which is used to measure canine obesity.

Three hundred six canine medical records were obtained from Spectrum Lab Japan (Tokyo, Japan) which provides examination services for animals. We created a database of individual dog's information (age, sex, neuter status, BCS, breed, lipid value of each lipoprotein (CM, VLDL, LDL, HDL) and fasting time) that was recorded when they received the lipoprotein analysis service (LipoTEST) from 2008 to 2016. The evaluation of BCS was carried out by each dog's veterinarian using a 5-point scale (1: thin, 2: underweight, 3: ideal, 4: overweight, 5: obese). LipoTEST was performed by Skylight Biotech Inc. (Akita, Japan), and Cho and TG concentrations were measured using gel filtering high performance liquid chromatography \[[@r12], [@r20]\].

To ensure that the results were not affected by data from dogs that had eaten recently, we excluded samples if the fasting time was less than eight hours. Recent research indicated that CM-TG concentrations were higher when fasting times were less than eight hours, due to exogenous lipids \[[@r21]\]. To evaluate CF efficacy, we collected records of each lipoprotein's lipid concentrations before and after the first medication, ensuring that the two measurements were performed within one year. In addition, all dogs were prescribed CF at 10 mg/kg/BID by each veterinarian. The database was divided into four subsets based on breed. There were three main breed subsets for Miniature Schnauzers, Toy Poodles and Shih Tzus, and a fourth subset containing 26 additional breeds and mixed breeds.

All statistical analyses were performed using EZR version 1.35 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) statistics software which has expanded R and R commander functions \[[@r8]\]. *P*\<0.05 was considered to be significant. To evaluate the reduction in lipid level from using CF, we applied the Wilcoxon signed-rank test because all differences between lipid concentrations before and after medication showed non-normal distribution. Total TG reduction rate ((before dosage−after dosage)/ before dosage) also showed non-normal distribution, so we performed a multivariate logistic regression analysis in relation to drug response, instead of a multiple regression analysis in relation to total TG reduction rate. Then we divided samples into two groups according to the presence or absence of drug efficacy using the total TG reduction rate. For the grouping, we created a model of whether the total TG reduction rate was positive or not. Multivariate logistic regression analysis was used to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs) after controlling simultaneously for potential confounders. Variables considered in the models were a dog's characteristics (age, breed, BCS, sex, and neuter status) and pre-dose total TG concentration. We excluded 34 records with incomplete information about dog characteristics from the Multivariate logistic regression analysis. For age, we divided samples into two groups; up to seven years old and more than seven years old. Samples with total TG concentration of more than 500 mg/d*l* were defined as severe dyslipidemia.

Three hundred six dogs met the criteria for the data set, comprising 62 Miniature Schnauzers, 47 Toy Poodles, 25 Shih Tzus and 172 others. The dogs' characteristics and lipid data are summarized in [Tables 1](#tbl_001){ref-type="table"}Table 1.Details of dog samplesRecords of 306 dogsN%BreedMiniature Schnauzer (MSC)6220.26Toy Poodle (TPO)4715.36Shih Tzu (STZ)258.17Other (OTR)17256.21SexMale (M)12841.83Female (F)17657.52Unknown20.65Neuter statusIntact5517.97Neutered24981.37Unknown20.65BCS2: underweight61.963: ideal9330.394: overweight12440.525: obese5116.67Unknown3210.46BCS, Body Condition Score with 5-point scale (1--5). and [2](#tbl_002){ref-type="table"}Table 2.Canine characteristics and lipid concentrations of each breedMSCTPOSTZOTRTotal(62 dogs)(47 dogs)(25 dogs)(172 dogs)(306 dogs)Age9.75^a)^ (2.00--12.75)6.17^b)^ (1.58--14.08)11.25 (2.00--14.58)9.00 (1.50--16.92)9.08 (1.50--16.92)Sex10 MI, 16 MN5 MI, 21 MN3 MI, 8 MN11 MI, 54 MN29 MI, 99 MN6 FI, 30 FN2 FI, 18 FN, 1 UR5 FI, 8 FN, 1 UR13 FI, 94 FN26 FI, 150 FN, 2 URBCS221036326173479342118157012456343851Unknown7831432Total cholesterol294.19 (163.45--800.74)292.19 (139.47--1,076.07)288.69 (152.16--896.25)269.48 (132.86--2,287.30)276.47 (132.86--2,287.30)Total triglyceride633.90^c)^ (108.95--6,011.71)374.61 (95.76--2,507.12)405.77 (139.40--1,697.16)277.34 (79.69--5,095.56)355.20 (79.69--6,011.71)MSC, Miniature Schnauzer; TPO, Toy Poodle; STZ, Shih Tzu; OTR, Other Breed; MI, Male intact; MN, Male neutered; FI, Female intact; FN, Female neutered; UR, unreported sex status; BCS, Body Condition Score with 5-point scale (1−5). All lipid values show pre-dosage concentrations. Values are median (range) for age (years), total cholesterol concentration (mg/d*l*), and each triglyceride concentration (mg/d*l*). a) Significantly different from STZ (*P*\<0.05). b) Significantly different from the other three breed groups (*P*\<0.001). c) Significantly different from OTR (*P*\<0.00001).. Miniature Schnauzers, which have a hereditary tendency to suffer from hypertriglyceridemia \[[@r13], [@r24], [@r25]\], had higher total TG levels than any other breed group (*P*\<0.00001). Toy Poodles were younger than the other breed groups (*P*\<0.001), and Shih Tzus were older than Miniature Schnauzers (*P*\<0.05) ([Table 2](#tbl_002){ref-type="table"}).

There was little knowledge about the efficacy of CF on each lipoprotein, so we evaluated the effects using the Wilcoxon signed-rank test. All statistical analyses showed significant reductions in lipoprotein concentrations after CF treatment ([Tables 3](#tbl_003){ref-type="table"}Table 3.Cholesterol concentrations before and after Clinofibrate medicationPre-dosage lipid value\
(mg/d*l*)Post-dosage lipid value\
(mg/d*l*)Difference (mg/d*l*)\
(Wilcoxon signed-rank test)CholesterolTotalMedian 276.47Median 222.32Median 46.60Mean 318.91Mean 253.41V=39,300, *P*=1.81 × 10^−24^Range 132.86--2,287.30Range 66.62--1,695.04CMMedian 2.68Median 0.84Median 1.22Mean 6.61Mean 3.22V=38,162, *P*=2.67 × 10^−21^Range 0.15--141.74Range 0.04--68.54VLDLMedian 27.07Median 13.55Median 8.95Mean 52.48Mean 27.33V=40,308, *P*=1.80 × 10^−27^Range 6.39--1,775.01Range 1.33--905.41LDLMedian 44.77Median 25.00Median 10.79Mean 69.61Mean 50.52V=36,165, *P*=2.72 × 10^−16^Range 4.57--513.16Range 2.04--535.46HDLMedian 190.45Median 169.27Median 16.48Mean 190.05Mean 172.34V=36,286, *P*=1.41 × 10^−16^Range 49.03--314.91Range 60.82--314.69CM, Chylomicrons triglyceride concentration; VLDL, Very low density lipoprotein triglyceride concentration; LDL, Low density lipoprotein triglyceride concentration; HDL, High density triglyceride lipoprotein triglyceride concentration. and [4](#tbl_004){ref-type="table"}Table 4.Triglyceride concentrations before and after Clinofibrate medicationPre-dosage lipid value\
(mg/d*l*)Post-dosage lipid value\
(mg/d*l*)Difference (mg/d*l*)\
(Wilcoxon signed-rank test)TriglycerideTotalMedian 355.20Median 161.85Median 125.15Mean 554.05Mean 308.44V=40,703, *P*=1.06 × 10^−28^Range 79.89--6,011.71Range 22.53--4,356.71CMMedian 36.61Median 8.82Median 18.25Mean 94.21Mean 45.53V=38,077, *P*=4.53 × 10^−21^Range 0.61--2,327.52Range 0.19--1,137.74VLDLMedian 266.04Median 124.87Median 102.39Mean 412.41Mean 230.68V=40,897, *P*=2.59 × 10^−29^Range 67.55--4,457.40Range 4.84--3,539.90LDLMedian 20.36Median 17.61Median 2.91Mean 32.59Mean 23.33V=31,208, *P*=6.17 × 10^−7^Range 4.07--333.07Range 3.13--237.98HDLMedian 10.63Median 5.47Median 3.49Mean 15.56Mean 8.86V=39,715, *P*=1.10 × 10^−25^Range 2.30--178.34Range 0.98--92.06CM, Chylomicrons triglyceride concentration; VLDL, Very low density lipoprotein triglyceride concentration; LDL, Low density lipoprotein triglyceride concentration; HDL, High density triglyceride lipoprotein triglyceride concentration.). These results clarified that CF can improve dogs' lipid metabolism in each lipoprotein, and particularly decrease VLDL-TG concentration (Median difference=102.39, *P*=2.59 × 10^−29^; [Table 4](#tbl_004){ref-type="table"}). CF improved VLDL-TG concentrations in 256 of the 306 dogs, with a mean reduction rate of 54.82% (median reduction rate=57.43) (data not shown). Cho and TG concentrations were reduced in 239 and 252 dogs, respectively, with mean reduction rates of 27.00 and 53.70% (median reduction rate=24.15 and 54.71, respectively) (data not shown). Fibrates have a similar molecular structure to human PPARα agonist, which regulates some lipid metabolism related genes such as *lipoprotein lipase* (*LPL*), *apolipoprotein C3* (*APOC3*), and *apolipoprotein A5* (*APOA5*) \[[@r16], [@r23]\]. These genes regulate the quantity of VLDL, consist abundantly with TGs, so fibrates are particularly able to decrease VLDL-TG levels. The dog PPARα is likely to be similar to human PPARα. There is a 97% homology between dog PPARα and human PPARα amino acid sequences \[[@r14]\], so the CF treatment in the dogs may have acted as a dog PPARα agonist causing homeostasis of lipid metabolism, similar to the effect of human CF treatment.

However, 17.65% of all dogs (n=54) showed CF refractoriness in total TG level, so we performed multivariate logistic regression analyses using dog characteristics and pre-dosage total TG values. The model comprised 272 dogs, of which 48 showed drug refractoriness. Sample information in the model is summarized in [Table 5](#tbl_005){ref-type="table"}Table 5.Comparisons between canine characteristics of dogs with and without drug responseCanine characteristicsDrug responseYes\
(224 dogs)No\
(48 dogs)BreedMSC4411TPO2513STZ192OTR13622Age9.08 (1.50--16.92)9.34 (3.00--15.08)\<76010≥716438Sex23 MI, 70 MN3 MI, 19 MN21 FI, 110 FN3 FI, 23 FNBCS2513712241081454011T-Cho276.47 (132.86--2,287.30)295.66 (139.47--1,076.07)T-TG369.45 (83.84--6,011.71)281.55 (79.69--2,895.11)VLDL-TG294.94 (70.30--4,457.40)220.37 (67.55--1,852.84)MSC, Miniature Schnauzer; TPO, Toy Poodle; STZ, Shih Tzu; OTR, Other Breed; MI, Male intact; MN, Mail neutered; FI, Female intact; FN, Female neutered; BCS, Body Condition Score with 5-point scale (1−5); T-Cho, Total cholesterol concentration; T-TG, Total triglyceride concentration; VLDL-TG, Very low density lipoprotein triglyceride concentration. T-Cho, T-TG, and VLDL-TG showed pre-dosage concentrations. Values are median (range) for age (years), total cholesterol concentration (mg/d*l*), and each triglyceride concentration (mg/d*l*).. Multivariate logistic regression analysis indicated that breed and pre-dosage total TG values were independently related to CF response, but other dog characteristics were not associated with CF efficacy ([Table 6](#tbl_006){ref-type="table"}Table 6.Risk factors for Clinofibrate refractorinessRisk factorsOdds ratio (95% CI)*P*-value(Intercept)0.08 (0.02--0.33)\<0.001Age\<7Reference≥72.44 (0.98--6.08)\<0.1BCSAll0.1920.46 (0.04--5.16)3Reference40.48 (0.22--1.04)51.12 (0.46--2.74)BreedAll\<0.005OTRReferenceMSC1.91 (0.79--4.60)0.15STZ0.71 (0.15--3.43)0.72TPO5.36 (2.07--13.90)\<0.001Before\<500ReferenceTotal-TG≥5000.37 (0.17--0.82)\<0.05Neuter statusIntactReferenceNeutered1.56 (0.59--4.15)0.37SexFemaleReferenceMale1.09 (0.55--2.16)0.80BC3S, Body Condition Score with 5-point scale (1--5); OTR, Other Breed; MSC, Miniature Schnauzer; STZ, Shih Tzu; TPO, Toy Poodle. Before Total-TG shows pre-dosage concentration (mg/d*l*).). Toy Poodles had a higher risk of showing CF refractoriness compared with the other breed groups, with an OR of 5.36 (95% CI=2.07--13.90). Toy Poodles are well known to be susceptible to diabetes mellitus \[[@r22]\], a disease related to dyslipidemia \[[@r1], [@r24]\]. Furthermore, there was a greater CF response with the severe dyslipidemia group than with the dogs without severe dyslipidemia (OR=0.37, 95% CI=0.17--0.82). This result is in accordance with a previous study on Bezafibrate response for canine dyslipidemia \[[@r3]\].

The reason why Toy Poodles had lower CF response than the other breeds may have been due to anamnesis, such as diabetes mellitus. The present study did not take anamnesis into account, but other studies have shown that insulin-resistant dogs have lower *LPL* mRNA expression levels than insulin-sensitive dogs \[[@r4], [@r18]\]. So diabetes mellitus might have affected CF efficacy in the current study. Furthermore, there have been various studies about the relationship between canine diabetes mellitus and some gene variations such as *cytotoxic T lymphocyte-associated antigen 4* and *dog leukocyte antigen* \[[@r2], [@r9], [@r19]\]. So genetic variants may possibly be related to CF response. Further analysis is needed with such disease information included in the dataset.

Although the current study considered fasting time in order to exclude effect of exogenous lipids, it was not possible to eliminate environment factors such as exercise. However, despite this the results seem to indicate that genetics can affect drug efficacy, because breed was most strongly correlated with CF resistance.

In recent years pharmacogenetic studies have often been conducted on humans, and the relevance of drug response and gene polymorphisms in fibrates has also been clarified. For example, human *APOA5* mutations have been shown to be correlated with the fibrates efficacy \[[@r5], [@r11]\]. *APOA5* is a target gene for PPARα, and human *APOA5* has a PPAR response element (PPRE) in the promoter region \[[@r23]\]. Furthermore, some studies have indicated that human *APOA5* has a big influence on lipid and lipoprotein metabolism \[[@r10], [@r15]\]. Therefore, it is possible that a similar response occurs in dogs.

In conclusion, this study suggests that genetic factors may affect CF response. Therefore, genetic studies might be performed on some genes which related to lipid metabolism and diabetes mellitus to identify variations in CF efficacy in dogs. Such studies, together with further epidemiological studies are needed to make better treatment plans for lipid metabolism disorders in dogs.
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